

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 December 2003 (04.12.2003)

PCT

(10) International Publication Number  
**WO 03/099760 A1**

- (51) International Patent Classification<sup>7</sup>: **C07C 69/63**
- (21) International Application Number: PCT/US03/15996
- (22) International Filing Date: 21 May 2003 (21.05.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/382,075 22 May 2002 (22.05.2002) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 60/382,075 (CON)  
Filed on 22 May 2002 (22.05.2002)
- (71) Applicant (for all designated States except US): **BEACON LABORATORIES, INC.** [US/US]; c/o First Solar, 4050 East Cotton Center Blvd., Phoenix, AZ 85040 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LAN-HARGEST, Hsuan-Yin** [US/US]; 2901 Sedgefield Court, Fallston, MD 21047 (US). **KAUFMAN, Robert, J.** [US/US]; 8129 Stanford Avenue, St. Louis, MO 63130 (US).
- (74) Agent: **FOX, Harold, H.**; Fish & Richardson P.C., 1425 K Street NW, 11th Floor, Washington, DC 20005-3500 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 03/099760 A1**

(54) Title: HISTONE DEACETYLASE INHIBITORS BASED ON TRIHALOMETHYLCARBONYL COMPOUNDS

(57) Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, a trihalomethylcarbonyl group, such as a trifluoromethylcarbonyl group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemaglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or for stimulating hematopoietic cellsex vivo.

## HISTONE DEACETYLASE INHIBITORS BASED ON TRIHALOMETHYLCARBONYL COMPOUNDS

### 5 TECHNICAL FIELD

This invention relates to trihalomethylcarbonyl compounds, and more particularly to trihalomethylcarbonyl compounds that are histone deacetylase inhibitors.

### BACKGROUND

10 DNA in the nucleus of the cell exists as a hierarchy of compacted chromatin structures. The basic repeating unit in chromatin is the nucleosome. The nucleosome consists of a histone octamer of proteins in the nucleus of the cell around which DNA is wrapped twice. The orderly packaging of DNA in the nucleus plays an important role in the functional aspects of gene regulation. Covalent modifications of the  
15 histones have a key role in altering chromatin higher order structure and function and ultimately gene expression. The covalent modification of histones, such as acetylation, occurs by enzymatically mediated processes.

Regulation of gene expression through the inhibition of the nuclear enzyme histone deacetylase (HDAC) is one of several possible regulatory mechanisms  
20 whereby chromatin activity can be affected. The dynamic homeostasis of the nuclear acetylation of histones can be regulated by the opposing activity of the enzymes histone acetyl transferase (HAT) and histone deacetylase (HDAC). Transcriptionally silent chromatin can be characterized by nucleosomes with low levels of acetylated histones. Acetylation reduces the positive charge of histones, thereby expanding the  
25 structure of the nucleosome and facilitating the interaction of transcription factors with the DNA. Removal of the acetyl group restores the positive charge, condensing the structure of the nucleosome. Histone acetylation can activate DNA transcription, enhancing gene expression. Histone deacetylase can reverse the process and can serve to repress gene expression. See, for example, Grunstein, *Nature* 389, 349-352


(1997); Pazin et al., *Cell* 89, 325-328 (1997); Wade et al., *Trends Biochem. Sci.* 22, 128-132 (1997); and Wolffe, *Science* 272, 371-372 (1996).

### SUMMARY

Histone deacetylase is a metallo-enzyme with zinc at the active site.

- 5 Compounds having a zinc-binding moiety, for example, a trihalomethylcarbonyl group such as a trifluoromethylcarbonyl group, can inhibit histone deacetylase. Histone deacetylase inhibition can alter gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g.,
- 10 hemoglobinopathies, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, autosomal dominant disorders, e.g. Huntington's disease and spinal muscular atrophy, or for stimulating hematopoietic cells *ex vivo*.

In one aspect, a compound has the formula (I):



- 15 In another aspect, method of inhibiting histone deacetylation activity in cells includes contacting the cells with an effective amount of a compound containing a trihalomethylcarbonyl group, thereby treating one or more disorders mediated by histone deacetylase or stimulating hematopoietic cells *ex vivo*, and determining whether the level of acetylated histones in the treated cells is higher than in untreated
- 20 cells under the same conditions. The compound can be of formula (I). In the method, the compound can be 1,1,1-trifluoro-5-phenyl-2-pentanone, 1,1,1-trifluoro-8-phenyl-3,5,7-octatrien-2-one, or 1,1,1-trifluoro-8-phenoxy-3,5,7-octatrien-2-one. The disorder can be cancer, hemoglobinopathies, thalassemia, sickle cell anemia, cystic fibrosis, protozoan infection, spinal muscular atrophy, Huntington's disease, alpha-1
- 25 anti-trypsin, retrovirus gene vector reactivation, wound healing, hair growth, peroxisome biogenesis disorder, or adrenoleukodystrophy.

In formula (I), A is a cyclic moiety selected from the group consisting of C<sub>3-14</sub> cycloalkyl, 3-14 membered heterocycloalkyl, C<sub>4-14</sub> cycloalkenyl, 3-8 membered

heterocycloalkenyl, aryl, or heteroaryl. The cyclic moiety is optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, thio, alkylthio, arylthio, aralkylthio, acylthio, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl. Alternatively, A

5 is a saturated branched C<sub>3-12</sub> hydrocarbon chain or an unsaturated branched C<sub>3-12</sub> hydrocarbon chain optionally interrupted by -O-, -S-, -N(R<sup>a</sup>)-, -C(O)-, -N(R<sup>a</sup>)-SO<sub>2</sub>-, -SO<sub>2</sub>-N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-O-, -O-C(O)-N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-N(R<sup>b</sup>)-, -O-C(O)-, -C(O)-O-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, or -O-C(O)-O-. Each of R<sup>a</sup> and R<sup>b</sup>, independently, can be hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl.

10 Each of the saturated and the unsaturated branched hydrocarbon chain is optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, thio, alkylthio, arylthio, aralkylthio, acylthio, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl.

15 In formula (I), each of Y<sup>1</sup> and Y<sup>2</sup>, independently, is -O-, -S-, -N(R<sup>c</sup>)-, -N(R<sup>c</sup>)-C(O)-O-, -N(R<sup>c</sup>)-C(O)-, -C(O)-N(R<sup>c</sup>)-, -O-C(O)-N(R<sup>c</sup>)-, -N(R<sup>c</sup>)-C(O)-N(R<sup>d</sup>)-, -O-C(O)-O-, or a bond. Each of R<sup>c</sup> and R<sup>d</sup>, independently, can be hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl.

In formula (I), L is a straight C<sub>3-12</sub> hydrocarbon chain optionally containing at

20 least one double bond, at least one triple bond, or at least one double bond and one triple bond. The hydrocarbon chain can be optionally substituted with C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, hydroxyl, halo, amino, thio, alkylthio, arylthio, aralkylthio, acylthio, nitro, cyano, C<sub>3-5</sub> cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C<sub>1-4</sub> alkylcarbonyloxy, C<sub>1-4</sub>

25 alkyloxycarbonyl, C<sub>1-4</sub> alkylcarbonyl, or formyl. The hydrocarbon chain can be optionally interrupted by -O-, -N(R<sup>e</sup>)-, -N(R<sup>e</sup>)-C(O)-O-, -O-C(O)-N(R<sup>e</sup>)-, -N(R<sup>e</sup>)-C(O)-N(R<sup>f</sup>)-, or -O-C(O)-O-. Each of R<sup>e</sup> and R<sup>f</sup>, independently, can be hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl.

In formula (I), X<sup>1</sup> is O or S.

In formula (I), when  $Y^1$  and  $Y^2$  are each a bond, L is a  $C_{6-12}$  hydrocarbon chain containing at least one double bond at C1, C2, C3 or C5 of the hydrocarbon chain from  $C=X^1$ , at least one triple bond, or at least one double bond and one triple bond.

In certain circumstances:  $X^2$  can be fluorine;  $Y^1$  can be not a bond; each of  $Y^1$  and  $Y^2$ , independently, can be -O-, -N(R<sup>c</sup>)-, or a bond;  $X^1$  can be O; L can be a  $C_{6-8}$  hydrocarbon chain substituted with  $C_{1-2}$  alkyl,  $C_{1-2}$  alkoxy, hydroxyl, -NH<sub>2</sub>, -NH( $C_{1-2}$  alkyl), or -N( $C_{1-2}$  alkyl)<sub>2</sub>; L can be a  $C_{4-12}$  hydrocarbon chain; L can be a  $C_{5-12}$  hydrocarbon chain; L can be a  $C_{5-10}$  hydrocarbon chain, L can be an unsaturated hydrocarbon chain containing at least two double bonds; or A can be a  $C_{5-8}$  cycloalkenyl, 5-8 membered heteroalkenyl, phenyl, naphthyl, indanyl, or tetrahydronaphthyl optionally substituted with alkyl alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, or amino.

In certain circumstances, A is phenyl,  $Y^1$  is a bond, and L is a  $C_{6-12}$  hydrocarbon chain containing three double bonds and the carbon adjacent to  $Y^1$  is substituted with phenyl. In other circumstances, A is phenyl,  $Y^1$  is a bond, and L is a  $C_{3-12}$  hydrocarbon chain and the carbon adjacent to  $Y^1$  is substituted with two phenyls.

In formula (I), the compound can be 1,1,1-trifluoro-8-phenyl-3,5,7-octatrien-2-one or 1,1,1-trifluoro-8-phenoxy-3,5,7-octatrien-2-one.

A salt of any of the compounds can be prepared. For example, a pharmaceutically acceptable salt can be formed when an amino-containing compound of this invention reacts with an inorganic or organic acid. Some examples of such an acid include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, *p*-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, and acetic acid. Examples of pharmaceutically acceptable salts thus formed include sulfate, pyrosulfate bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, and maleate. A compound of this invention may also form a pharmaceutically acceptable salt when a compound of this invention having an acid

moiety reacts with an inorganic or organic base. Such salts include those derived from inorganic or organic bases, e.g., alkali metal salts such as sodium, potassium, or lithium salts; alkaline earth metal salts such as calcium or magnesium salts; or ammonium salts or salts of organic bases such as morpholine, piperidine, pyridine, 5 dimethylamine, or diethylamine salts.

It should be recognized that a compound of the invention can contain chiral carbon atoms. In other words, it may have optical isomers or diastereoisomers.

Alkyl is a straight or branched hydrocarbon chain containing 1 to 10 (preferably, 1 to 6; more preferably 1 to 4) carbon atoms. Examples of alkyl include, 10 but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylhexyl, and 3-ethyl-octyl.

Alkenyl and alkynyl refer to a straight or branched hydrocarbon chain containing 2 to 10 carbon atoms and one or more (preferably, 1-4 or more preferably 1-2) double or triple bonds, respectively. Some examples of alkenyl and alkynyl are 15 allyl, 2-butenyl, 2-pentenyl, 2-hexenyl, 2-butylnyl, 2-pentynyl, and 2-hexynyl.

Cycloalkyl is a monocyclic, bicyclic or tricyclic alkyl group containing 3 to 14 carbon atoms. Some examples of cycloalkyl are cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, and norbornyl. Heterocycloalkyl is a cycloalkyl group containing at least one heteroatom (e.g., 1-3) such as nitrogen, oxygen, or 20 sulfur. The nitrogen or sulfur may optionally be oxidized and the nitrogen may optionally be quaternized. Examples of heterocycloalkyl include piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrofuryl, and morpholinyl. Cycloalkenyl is a cycloalkyl group containing at least one (e.g., 1-3) double bond. Examples of such a group include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, and cyclooctenyl 25 groups. By the same token, heterocycloalkenyl is a cycloalkenyl group containing at least one heteroatom selected from the group of oxygen, nitrogen or sulfur.

Aryl is an aromatic group containing a 5-14 member ring and can contain fused rings, which may be saturated, unsaturated, or aromatic. Examples of an aryl group include phenyl, naphthyl, biphenyl, phenanthryl, and anthracyl. If the aryl is

specified as "monocyclic aryl," if refers to an aromatic group containing only a single ring, i.e., not a fused ring.

Heteroaryl is aryl containing at least one (e.g., 1-3) heteroatom such as nitrogen, oxygen, or sulfur and can contain fused rings. Some examples of heteroaryl  
5 are pyridyl, furanyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, benzofuranyl, and benzthiazolyl.

The cyclic moiety can be a fused ring formed from two or more of the just-mentioned groups. Examples of a cyclic moiety having fused rings include fluorenyl, dihydro-dibenzoazepine, dibenzocycloheptenyl, 7H-pyrazino[2,3-c]carbazole, or  
10 9,10-dihydro-9,10-[2]buteno-anthracene.

Amino protecting groups and hydroxy protecting groups are well-known to those in the art. In general, the species of protecting group is not critical, provided that it is stable to the conditions of any subsequent reaction(s) on other positions of the compound and can be removed without adversely affecting the remainder of the  
15 molecule. In addition, a protecting group may be substituted for another after substantive synthetic transformations are complete. Examples of an amino protecting group include, but not limited to, carbamates such as 2,2,2-trichloroethylcarbamate or tertbutylcarbamate. Examples of a hydroxyl protecting group include, but not limited to, ethers such as methyl, t-butyl, benzyl, p-methoxybenzyl, p-nitrobenzyl, allyl, trityl,  
20 methoxymethyl, 2-methoxypropyl, methoxyethoxymethyl, ethoxyethyl, tetrahydropyranyl, tetrahydrothiopyranyl, and trialkylsilyl ethers such as trimethylsilyl ether, triethylsilyl ether, dimethylarylsilyl ether, triisopropylsilyl ether and t-butyl dimethylsilyl ether; esters such as benzoyl, acetyl, phenylacetyl, formyl, mono-, di-, and trihaloacetyl such as chloroacetyl, dichloroacetyl, trichloroacetyl,  
25 trifluoroacetyl; and carbonates including but not limited to alkyl carbonates having from one to six carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl; isobutyl, and n-pentyl; alkyl carbonates having from one to six carbon atoms and substituted with one or more halogen atoms such as 2,2,2-trichloroethoxymethyl and 2,2,2-trichloro-ethyl; alkenyl carbonates having from two to six carbon atoms  
30 such as vinyl and allyl; cycloalkyl carbonates having from three to six carbon atoms

such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; and phenyl or benzyl carbonates optionally substituted on the ring with one or more C<sub>1-6</sub> alkoxy, or nitro. Other protecting groups and reaction conditions can be found in T. W. Greene, *Protective Groups in Organic Synthesis*, (3rd, 1999, John Wiley & Sons, New York, N.Y.).

Note that an amino group can be unsubstituted (i.e., -NH<sub>2</sub>), mono-substituted (i.e., -NHR), or di-substituted (i.e., -NR<sub>2</sub>). It can be substituted with groups (R) such as alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl. Halo refers to fluoro, chloro, bromo, or iodo.

Inhibition of a histone deacetylase in a cell is determined by measuring the level of acetylated histones in the treated cells and measuring the level of acetylated histones in untreated cells and comparing the levels. If the level of histone acetylation in the treated cells increases relative to the untreated cells, histone deacetylase has been inhibited.

Some disorders or physiological conditions may be mediated by hyperactive histone deacetylase activity. A disorder or physiological condition that is mediated by histone deacetylase refers to a disorder or condition wherein histone deacetylase plays a role in triggering the onset thereof. Examples of such disorders or conditions include, but not limited to, cancer, hemoglobinopathies (e.g., thalassemia or sickle cell anemia), cystic fibrosis, protozoan infection, spinal muscular atrophy, Huntington's disease, alpha-1 anti-trypsin, retrovirus gene vector reactivation, wound healing, hair growth, peroxisome biogenesis disorder, and adrenoleukodystrophy.


Other features or advantages will be apparent from the following detailed description of several embodiments, and also from the appended claims.

## DETAILED DESCRIPTION

The compounds of formula (I) can generally be prepared according to the following methods. The trihalomethylcarbonyl compounds can be prepared from an aldehyde as shown in Scheme A. In particular, the trihalomethylcarbonyl compound can be prepared by reacting the aldehyde in THF with an equal amount of acetic acid




and piperidine followed by addition of 1,1,1-trifluoroacetone at room temperature under nitrogen.



**Scheme A**

- 5 The carbon-carbon double bond can be selectively reduced or otherwise modified. The aldehyde can be prepared, for example, from a carboxylic acid-containing compound. These compound can be prepared by any method known in the art. For example, a compound having an unsaturated hydrocarbon chain between A and  $-\text{C}(=\text{X}^1)-$  can be prepared according to scheme B:



10

**Scheme B**

- where L' is a saturated or unsaturated hydrocarbon linker between A and  $-\text{CH}=\text{CH}-$  in a compound of the invention, and A and X<sup>1</sup> has the same meaning as defined above. See Coutrot et al., *Syn. Comm.* 133-134 (1978). Briefly, butyllithium is added to an appropriate amount of anhydrous tetrahydrofuran (THF) at a very low temperature (e.g., -65°C). A second solution having diethylphosphonoacetic acid in anhydrous THF is added dropwise to the stirred butyllithium solution at the same low temperature. The resulting solution is stirred at the same temperature for an additional 30-45 minutes which is followed by the addition of a solution containing an aromatic acrylaldehyde in anhydrous THF over 1-2 hours. The reaction mixture is then warmed to room temperature and stirred overnight. It is then acidified (e.g., with

20

HCl) which allows the organic phase to be separated. The organic phase is then dried, concentrated, and purified (e.g., by recrystallization) to form an unsaturated carboxylic acid.

Alternatively, a carboxylic acid-containing compound can be prepared by reacting an acid ester of the formula A-L'-C(=O)-O-lower alkyl with a Grignard reagent (e.g., methyl magnesium iodide) and a phosphorus oxychloride to form a corresponding aldehyde, which can be further oxidized (e.g., by reacting with silver nitrate and aqueous NaOH) to form an unsaturated carboxylic acid.

Other types of carboxylic acid-containing compounds (e.g., those containing a linker with multiple double bonds or triple bonds) can be prepared according to published procedures such as those described, for example, in Parameswara et al., *Synthesis*, 815-818 (1980) and Denny et al., *J. Org. Chem.*, 27, 3404 (1962). As to compounds wherein X<sup>1</sup> is S, they can be prepared according to procedures described in Sandler, S. R. and Karo, W., *Organic Functional Group Preparations, Volume III* (Academic Press, 1972) at pages 436-437. Additional synthetic methods can be found in March, J. *Advanced Organic Chemistry*, 4<sup>th</sup> ed., (Wiley Interscience, 1992).

Note that appropriate protecting groups may be needed to avoid forming side products during the preparation of a compound of the invention. For example, if the linker L' contains an amino substituent, it can be first protected by a suitable amino protecting group such as trifluoroacetyl or *tert*-butoxycarbonyl prior to being treated with reagents such as butyllithium. See, e.g., T. W. Greene, *supra*, for other suitable protecting groups.

A compound produced by the methods shown above can be purified by flash column chromatography, preparative high performance liquid chromatography, or crystallization.

A pharmaceutical composition including the compound described above can be used to inhibit histone deacetylase in cells and can be used to treat disorders associated with abnormal histone deacetylase activity. Some examples of these disorders are cancers (e.g., leukemia, lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, cervical cancer, renal cancer, prostate cancer, and breast

cancer), hematological disorders (e.g., hemoglobinopathies, thalassemia, and sickle cell anemia), autosomal disorders (e.g. Huntington's disease and spinal muscular atrophy), and genetic related metabolic disorders (e.g., cystic fibrosis, spinal muscular atrophy, peroxisome biogenesis disorder, alpha-1 anti-trypsin, and  
5 adrenoleukodystrophy). The compounds described above can also stimulate hematopoietic cells *ex vivo*, ameliorating protozoal parasitic infection, accelerate wound healing, and protecting hair follicles.

An effective amount is defined as the amount which is required to confer a therapeutic effect on the treated patient, and is typically determined based on age,  
10 surface area, weight, and condition of the patient. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., *Cancer Chemother. Rep.* 50, 219 (1966). Body surface area may be approximately determined from height and weight of the patient. See, e.g., *Scientific Tables*, Geigy Pharmaceuticals, Ardsley, New York, 537 (1970). An  
15 effective amount of a compound described herein can range from about 1 mg/kg to about 300 mg/kg. Effective doses will also vary, as recognized by those skilled in the art, dependent on route of administration, excipient usage, and the possibility of co-usage, pre-treatment, or post-treatment, with other therapeutic treatments including use of other chemotherapeutic agents and radiation therapy. Other chemotherapeutic  
20 agents that can be co-administered (either simultaneously or sequentially) include, but not limited to, paclitaxel and its derivatives (e.g., taxotere), doxorubicin, L-asparaginase, dacarbazine, amascrine, procarbazine, hexamethylmelamine, mitoxantrone, and gemcitabine.

The pharmaceutical composition may be administered via the parenteral route,  
25 including orally, topically, subcutaneously, intraperitoneally, intramuscularly, and intravenously. Examples of parenteral dosage forms include aqueous solutions of the active agent, in a isotonic saline, 5% glucose or other well-known pharmaceutically acceptable excipient. Solubilizing agents such as cyclodextrins, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical  
30 excipients for delivery of the therapeutic compounds. Because some of the

compounds described herein can have limited water solubility, a solubilizing agent can be included in the composition to improve the solubility of the compound. For example, the compounds can be solubilized in polyethoxylated castor oil (Cremophor EL®) and may further contain other solvents, e.g., ethanol. Furthermore, compounds described herein can also be entrapped in liposomes that may contain tumor-directing agents (e.g., monoclonal antibodies having affinity towards tumor cells).

A compound described herein can be formulated into dosage forms for other routes of administration utilizing conventional methods. For example, it can be formulated in a capsule, a gel seal, or a tablet for oral administration. Capsules may contain any standard pharmaceutically acceptable materials such as gelatin or cellulose. Tablets may be formulated in accordance with conventional procedures by compressing mixtures of a compound described herein with a solid carrier and a lubricant. Examples of solid carriers include starch and sugar bentonite. Compounds of this invention can also be administered in a form of a hard shell tablet or a capsule containing a binder, e.g., lactose or mannitol, a conventional filler, and a tableting agent.

The activities of a compound described herein can be evaluated by methods known in the art, e.g., MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, clonogenic assay, ATP assay, or Extreme Drug Resistance (EDR) assay. See Freuhauf, J.P. and Manetta, A., *Chemosensitivity Testing in Gynecologic Malignancies and Breast Cancer* 19, 39 – 52 (1994). The EDR assay, in particular, is useful for evaluating the antitumor and antiproliferative activity of a compound described herein. Cells are treated for four days with a compound. Both untreated and treated cells are pulsed with tritiated thymidine for 24 hours. Radioactivity of each type of cells is then measured and compared. The results are then plotted to generate drug response curves, which allow  $IC_{50}$  values (the concentration of a compound required to inhibit 50% of the population of the treated cells) to be determined.

Histone deacetylase inhibitory activity can be measured based on procedures described by Hoffmann et al., *Nucleic Acids Res.*, 27, 2057-2058 (1999). Briefly, the

assay starts with incubating the isolated histone deacetylase enzyme with a compound of the invention, followed by the addition of a fluorescent-labeled lysine substrate (contains an amino group at the side chain which is available for acetylation). HPLC is used to monitor the labeled substrate. The range of activity of each test compound is preliminarily determined using results obtained from HPLC analyses. IC<sub>50</sub> values can then be determined from HPLC results using different concentrations of compounds of this invention. All assays are duplicated or triplicated for accuracy. The histone deacetylase inhibitory activity can be compared with the increased activity of acetylated histone for confirmation.

10        Compounds of this invention are also evaluated for effects on treating X-linked adrenoleukodystrophy (X-ALD), a peroxisomal disorder with impaired very long-chain fatty acid (VLCFA) metabolism. In such an assay, cell lines derived from human primary fibroblasts and (EBV-transformed lymphocytes) derived from X-ALD patients grown on RPMI are employed. Tissue culture cells are grown in the presence or absence of test compounds. For VLCFA measurements, total lipids are extracted, converted to methyl esters, purified by TLC and subjected to capillary GC analysis as described in Moser et al., *Technique in Diagnostic Biochemical Genetics: A Laboratory Manual* (ed. A., H.F.) 177-191 (Wiley-Liss, New York, 1991). C24:0  $\beta$ -oxidation activity of lymphoclastoid cells are determined by measuring their capacity to degrade [1-<sup>14</sup>C]-C24:0 fatty acid to water-soluble products as described in Watkins et al., *Arch. Biochem. Biophys.* 289, 329-336 (1991). The statistical significance of measured biochemical differences between untreated and treated X-ALD cells can be determined by a two-tailed Student's t-test.

25        Further, compounds of the present invention are evaluated for their effects in treating cystic fibrosis (CF). Since the initial defect in the majority of cases of CF is the inability of mutant CF protein (CFTR) to fold properly and exit the ER, compounds of the invention are tested to evaluate their efficacy in increasing the trafficking of the CF protein out of the ER and its maturation through the Golgi. During its biosynthesis, CFTR is initially synthesized as a nascent polypeptide chain in the rough ER, with a molecular weight of around 120 kDa (Band A). It rapidly

receives a core glycosylation in the ER, giving it a molecular weight of around 140 kDa (Band B). As CFTR exits the ER and matures through the Golgi stacks, its glycosylation is modified until it achieves a terminal mature glycosylation, affording it a molecular weight of around 170 kDa (Band C). Thus, the extent to which CFTR exits the ER and traverses the Golgi to reach the plasma membrane may be reflected in the ratio of Band B to Band C protein. CFTR is immunoprecipitated from control cells, and cells exposed to test compounds. Both *wt* CFTR and  $\Delta F508$  CFTR expressing cells are tested. Following lysis, CFTR is immunoprecipitated using various CFTR antibodies. Immunoprecipitates are then subjected to *in vitro* phosphorylation using radioactive ATP and exogenous protein kinase A. Samples are subsequently solubilized and resolved by SDS-PAGE. Gels are then dried and subject to autoradiography and phosphor image analysis for quantitation of Bands B and C are determined on a BioRad personal fix image station.

Furthermore, compounds of this invention can be used to treat homozygous  $\beta$  thalassemia, a disease in which there is inadequate production of  $\beta$  globin leading to severe anemia. See Collins et al., *Blood*, 85(1), 43-49 (1995).

Still further, compounds of the present invention are evaluated for their use as antiprotozoal or antiparasitic agents. The evaluation can be conducted using parasite cultures (e.g., Asexual *P. falciparum*). See Trager, W. & Jensen, J.B., *Science* 193, 673-675 (1976). Test compounds are dissolved in dimethyl sulfoxide (DMSO) and added to wells of a flat-bottomed 96-well microtitre plate containing human serum. Parasite cultures are then added to the wells, whereas control wells only contain parasite cultures and no test compound. After at least one invasion cycle, and addition of labeled hypoxanthine monohydrochloride, the level of incorporation of labeled hypoxanthine is detected.  $IC_{50}$  values can be calculated from data using a non-linear regression analysis.

The toxicity of a compound described herein is evaluated when a compound of the invention is administered by single intraperitoneal dose to test mice. After administration of a predetermined dose to three groups of test mice and untreated controls, mortality/morbidity checks are made daily. Body weight and gross necropsy

findings are also monitored. For reference, see Gad, S. C. (ed.), *Safety Assessment for Pharmaceuticals* (Van Nostrand Reinhold, New York, 1995).

The following specific examples, which described syntheses, screening, and biological testing of various compounds of this invention, are therefore, to be  
5 construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications recited herein, including patents, are hereby incorporated by reference in their entirety.

### Examples


#### Synthesis of 5-phenyl-2,4-pentadienal

10 To a cooled (0-5 °C) 927 mL of 1 M solution of phenyl magnesium bromide in tetrahydrofuran was added dropwise a solution of crotonaldehyde (65.0 g) in 130 mL of anhydrous ether over a period of 2 hours and 45 minutes. The reaction was stirred for an additional 45 minutes and then warmed to room temperature. After four more hours of stirring, saturated ammonium chloride aqueous solution (750 mL) was added  
15 to the reaction. The mixture was extracted with 750 mL of ether twice. The combined extract was dried over anhydrous potassium carbonate and filtered. The solvent was evaporated to give 135.88 g (99.9%) of the desired 1-phenyl-2-buten-1-ol as an oil which was used in the next step without further purification.

1-Phenyl-2-buten-1-ol (135.88 g) was dissolved in 2300 mL of dioxane and  
20 treated with 2750 mL of dilute hydrochloric acid (2.3 mL of concentrated hydrochloric acid in 2750 mL of water) at room temperature. The mixture was stirred overnight and then poured into 4333 mL of ether and neutralized with 2265 mL of saturated aqueous sodium bicarbonate. The aqueous phase was extracted with 1970 mL of ether. The combined extract was dried over anhydrous potassium carbonate.  
25 Evaporation of the solvent followed by Kugelrohr distillation at 30°C for 30 minutes afforded 131.73 g (96.8%) of the desired 4-phenyl-3-buten-2-ol as an oil which was used in the next step without further purification.

Dimethylformamide (DMF, anhydrous, 14 mL) was cooled to 0-5 °C and phosphorus oxychloride (8.2 mL) was added dropwise over a period of 40 minutes.

The resulting solution was added dropwise to a cooled (0-5°C) solution of 4-phenyl-3-buten-2-ol (10 g) in 32 mL of anhydrous DMF over a period of an hour. The reaction mixture was warmed to room temperature over a 35-minute period and then gradually heated up to 80°C over a period of 45 minutes. The reaction was stirred at 80°C for three hours and then cooled to 0-5°C. To the cooled reaction solution was added dropwise a solution of sodium acetate (40 g) in deionized water (100 mL) over a period of one hour. The mixture was then reheated to 80°C, stirred at 80°C for an additional 10 minutes, cooled down to room temperature and extracted with ether (100 mL) twice. The combined extract was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to yield 8.78 g of the desired 5-phenyl-2,4-pentadienal as a liquid which was used in the next step without further purification. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz), δ(ppm) 7.51 (m, 2H), 7.37 (m, 3H), 7.26 (m, 1H), 7.01 (m, 2H), 6.26 (m, 1H). The synthesis is summarized in Scheme I.



### Scheme I


#### Synthesis of 5-phenoxy-2,4-pentadienal

2-Formylvinyl phenyl ether is prepared by treating phenoxyacetaldehyde with formaldehyde and diethylamine hydrochloride salt. The ether is then reacting with a solution of diethylphosphonoacetic acid and n-butyllithium in anhydrous tetrahydrofuran (THF) to form 5-phenoxy-2,4-pentadienoic acid. 5-Phenoxy-2,4-pentadienal is obtained by first converting the carboxylic acid to a Weinreb amide using oxalyl chloride followed by N,O-dimethylhydroxylamine. Subsequently, reduction of the Weinreb amide with lithium aluminum hydride (LAH) in THF leads to the formation of 5-phenoxy-2,4-pentadienal. The synthesis is summarized in Scheme II.


20

25




**Scheme II**5 **Synthesis of 1,1,1-trifluoro-8-phenoxy-3,5,7-octatrien-2-one**

1,1,1-Trifluoro-8-phenoxy-3,5,7-octatrien-2-one is prepared as outlined in Scheme IIIA. 1,1,1-Trifluoro-8-phenoxy-3,5,7-octatrien-2-one is prepared by reacting 5-phenoxy-2,4-pentadienal in THF with an equal amount of acetic acid and piperidine followed by addition of 1,1,1-trifluoroacetone at room temperature under nitrogen.

**Scheme IIIA****Synthesis of 1,1,1-trifluoro-8-phenoxy-3,5,7-octatrien-2-one**

1,1,1-Trifluoro-8-phenoxy-3,5,7-octatrien-2-one is prepared in a similar manner, as shown in Scheme IIIB.

**Scheme IIIB**

### Assays

Compounds selected from 1,1,1-trifluoro-5-phenyl-2-pentanone (prepared according to the procedure described in *Biochim. Biophys. Acta* (1999), 1420 (1-2), 45-56), 1,1,1-trifluoro-8-phenyl-3,5,7-octatrien-2-one, and 1,1,1-trifluoro-8-phenoxy-3,5,7-octatrien-2-one are used in the assays described below.

#### *In vitro* Efficacy Studies – Extreme Drug Resistance (EDR) Assay

The PC3 cell line is maintained in RPMI supplemented with 10% fetal calf serum and antibiotics. Cells are suspended in 0.12% soft agar in complete medium and plated (2,000 cells per well) in different drug concentrations onto a 0.4% agarose underlayer in 24-well plates. Plating cells on agarose underlayers supports the proliferation only of the transformed cells, ensuring that the growth signal stems from the malignant component of the tumor.

All compounds are dissolved in DMSO to 200x stock solutions. Stock solutions are diluted to 20x working solutions using the tissue culture medium, then are serially diluted and added to the 24-well plates. The initial range of concentrations is 1 micromolar to 200 micromolar. No significant changes in pH of the culture medium are observed under the above conditions. Diluent control wells contain PC3 cells treated with DMSO, at the dilutions used for appropriate drug treatment. All experimental points are represented by two separate wells (duplicates). Four wells containing tumor cells that are not treated with drugs serve as negative controls in each experiment.

Cells are incubated with drugs under standard culture conditions for 5 days. Cultures are pulsed with tritiated thymidine ( $^3\text{H-TdR}$ , New Life Science Products, Boston, MA) at 5  $\mu\text{Ci}$  per well for the last 48 hours of the culture period. Cell culture plates are then heated to 90°C to liquefy the agarose, and cells are harvested onto glass fiber filters, which are then placed into counting vials containing liquid scintillation fluid. The radioactivity trapped on the filters is counted with a Beckman scintillation counter. The fraction of surviving cells is determined by comparing  $^3\text{H-TdR}$  incorporation in treated (experimental points) and untreated (negative control) wells. Microsoft Excel is used to organize the raw data on EDR experiments, and the

SigmaPlot program is utilized to generate drug response curves. All drug response curves are approximated as sigmoidal equations (characteristic for typical drug response curves) to fit the data. IC<sub>50</sub> values are determined using the approximated sigmoidal curves and expressed as  $\mu\text{M}$ .

5           **Histone (Hyper)Acetylation Assay**

The effect of a compound described herein on histone acetylation can be evaluated in an assay using mouse erythroleukemia cells. Studies are performed with the DS19 mouse erythroleukemia cells maintained in RPMI 1640 medium with 25 mM HEPES buffer and 5% fetal calf serum. The cells are incubated at 37°C.

10           Histones are isolated from cells after incubation for periods of 2 and 24 hours. The cells are centrifuged for 5 minutes at 2000 rpm in the Sorvall SS34 rotor and washed once with phosphate buffered saline. The pellets are suspended in 10 mL lysis buffer (10 mM Tris, 50 mM sodium bisulfite, 1% Triton X-100, 10 mM magnesium chloride, 8.6% sucrose, pH 6.5) and homogenized with six strokes of a  
15 Teflon pestle. The solution is centrifuged and the pellet washed once with 5 mL of the lysis buffer and once with 5 mL 10 mM Tris, 13 mM EDTA, pH 7.4. The pellets are extracted with 2 x 1 mL 0.25 N HCl. Histones are precipitated from the combined extracts by the addition of 20 mL acetone and refrigeration overnight. The histones are pelleted by centrifuging at 5000 rpm for 20 minutes in the Sorvall SS34 rotor.  
20 The pellets are washed once with 5 mL acetone and protein concentration are quantitated by the Bradford procedure.

Separation of acetylated histones is usually performed with an acetic acid-urea polyacrylamide gel electrophoresis procedure. Resolution of acetylated H4 histones is achieved with 6.25 N urea and no detergent as originally described by Panyim and  
25 Chalkley, *Arch. Biochem. Biophys.* 130, 337-346 (1969). 25  $\mu\text{g}$  Total histones are applied to a slab gel which is run at 20 mA. The run is continued for a further two hours after the Pyronin Y tracking dye has run off the gel. The gel is stained with Coomassie Blue R. The most rapidly migrating protein band is the unacetylated H4 histone followed by bands with 1, 2, 3 and 4 acetyl groups which can be quantitated  
30 by densitometry. The procedure for densitometry involves digital recording using the

Alpha Imager 2000, enlargement of the image using the PHOTOSHOP program (Adobe Corp.) on a MACINTOSH computer (Apple Corp.), creation of a hard copy using a laser printer and densitometry by reflectance using the Shimadzu CS9000U densitometer. The percentage of H4 histone in the various acetylated states is  
5 expressed as a percentage of the total H4 histone.

The concentration of a compound of the invention required to decrease the unacetylated H4 histone by 50% (i.e., EC<sub>50</sub>) can then be determined from data obtained using different concentrations of test compounds.

#### Histone Deacetylation Assay

10 The determination of the inhibition of histone deacetylase by compounds described herein is based upon the procedure described by Hoffmann et al., *Nucleic Acids Res.* 27, 2057-2058 (1999). The histone deacetylase is isolated from rat liver as previously described in Kolle, D. et al. *Methods: A Companion to Methods in Enzymology* 15: 323-331 (1998). Compounds are initially dissolved in either ethanol  
15 or in DMSO to provide a working stock solution. The synthetic substrate used in the assay is N-(4-methyl-7-coumarinyl)-N- $\alpha$ -(tert-butyloxy-carbonyl)-N- $\Omega$ -acetyllysineamide (MAL).


The assay is performed in a final total volume of 120  $\mu$ L consisting of 100  $\mu$ L of 15 mM tris-HCl buffer at pH 7.9 and 0.25 mM EDTA, 10 mM NaCl, 10% glycerol,  
20 10 mM mercaptoethanol and the enzyme. The assay is initiated upon the addition of 10  $\mu$ L of a test compound followed by the addition of a fluorescent-labeled lysine substrate to each assay tube in an ice bath for 15 minutes. The tubes are transferred to a water bath at 37 °C for an additional 90 minutes.

An initial assay is performed to determine the range of activity of each test  
25 compound. The determination of IC<sub>50</sub> values is made from the results of five dilutions in range according to the expected potency for each test compound. Each assay is duplicated or triplicated.

Other embodiments are within the scope of the following claims.

**WHAT IS CLAIMED IS:**

1. A compound having the formula (I):



wherein

- 5 A is a cyclic moiety selected from the group consisting of C<sub>3-14</sub> cycloalkyl, 3-14 membered heterocycloalkyl, C<sub>4-14</sub> cycloalkenyl, 3-8 membered heterocycloalkenyl, aryl, and heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, thio, alkylthio, arylthio, aralkylthio, acylthio, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or
- 10 alkylsulfonyl; or A is a saturated branched C<sub>3-12</sub> hydrocarbon chain or an unsaturated branched C<sub>3-12</sub> hydrocarbon chain optionally interrupted by -O-, -S-, -N(R<sup>a</sup>)-, -C(O)-, -N(R<sup>a</sup>)-SO<sub>2</sub>-, -SO<sub>2</sub>-N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-O-, -O-C(O)-N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-N(R<sup>b</sup>)-, -O-C(O)-, -C(O)-O-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, or -O-C(O)-O-, where each of R<sup>a</sup> and R<sup>b</sup>,
- 15 independently, is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl; each of the saturated and the unsaturated branched hydrocarbon chain being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, thio, alkylthio, arylthio, aralkylthio, acylthio, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl;
- 20

each of Y<sup>1</sup> and Y<sup>2</sup>, independently, is -O-, -S-, -N(R<sup>c</sup>)-, -N(R<sup>c</sup>)-C(O)-O-, -N(R<sup>c</sup>)-C(O)-, -C(O)-N(R<sup>c</sup>)-, -O-C(O)-N(R<sup>c</sup>)-, -N(R<sup>c</sup>)-C(O)-N(R<sup>d</sup>)-, -O-C(O)-O-, or a bond; each of R<sup>c</sup> and R<sup>d</sup>, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

- 25 L is a straight C<sub>3-12</sub> hydrocarbon chain optionally containing at least one double bond, at least one triple bond, or at least one double bond and one triple bond; the hydrocarbon chain being optionally substituted with C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, hydroxyl, halo, amino, thio, alkylthio, arylthio, aralkylthio,

acylthio, nitro, cyano, C<sub>3-5</sub> cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C<sub>1-4</sub> alkylcarbonyloxy, C<sub>1-4</sub> alkyloxycarbonyl, C<sub>1-4</sub> alkylcarbonyl, or formyl; and further being optionally interrupted by -O-, -N(R<sup>e</sup>)-, -N(R<sup>e</sup>)-C(O)-O-, -O-C(O)-N(R<sup>e</sup>)-, -N(R<sup>e</sup>)-C(O)-N(R<sup>f</sup>)-, or -O-C(O)-O-; each of R<sup>e</sup> and R<sup>f</sup>, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl; and

X<sup>1</sup> is O or S;


X<sup>2</sup> is a halogen;

provided that when Y<sup>1</sup> and Y<sup>2</sup> are each a bond, L is a C<sub>6-12</sub> hydrocarbon chain containing at least one double bond at C1, C2, C3 or C5 of the hydrocarbon chain from C=X<sup>1</sup>, at least one triple bond, or at least one double bond and one triple bond, the hydrocarbon chain being optionally substituted with C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, hydroxyl, halo, amino, thio, alkylthio, arylthio, aralkylthio, acylthio, nitro, cyano, C<sub>3-5</sub> cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C<sub>1-4</sub> alkylcarbonyloxy, C<sub>1-4</sub> alkyloxycarbonyl, C<sub>1-4</sub> alkylcarbonyl, or formyl; and further being optionally interrupted by -O-, -N(R<sup>e</sup>)-, -N(R<sup>e</sup>)-C(O)-O-, -O-C(O)-N(R<sup>e</sup>)-, -N(R<sup>e</sup>)-C(O)-N(R<sup>f</sup>)-, or -O-C(O)-O-; each of R<sup>e</sup> and R<sup>f</sup>, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

or a salt thereof.

2. The compound of claim 1, wherein X<sup>2</sup> is fluorine.
3. The compound of claim 1, wherein Y<sup>1</sup> is not a bond.
4. The compound of claim 1, wherein each of Y<sup>1</sup> and Y<sup>2</sup>, independently, is -O-, -N(R<sup>e</sup>)-, or a bond.
5. The compound of any of claims 1-4, wherein X<sup>1</sup> is O.
6. The compound of any of claims 1-6, wherein L is a C<sub>6-8</sub> hydrocarbon chain substituted with C<sub>1-2</sub> alkyl, C<sub>1-2</sub> alkoxy, hydroxyl, -NH<sub>2</sub>, -NH(C<sub>1-2</sub> alkyl), or -N(C<sub>1-2</sub> alkyl)<sub>2</sub>.

7. The compound of claim 1, wherein L is a C<sub>4-12</sub> hydrocarbon chain.
8. The compound of claim 1, wherein L is a C<sub>5-12</sub> hydrocarbon chain.
9. The compound of claim 1, wherein L is a C<sub>5-10</sub> hydrocarbon chain.
10. The compound of any of claims 1-9, wherein L is an unsaturated  
5 hydrocarbon chain containing at least two double bonds.
11. The compound of any of claims 1-10, wherein A is a C<sub>5-8</sub> cycloalkenyl, 5-8 membered heteroalkenyl, phenyl, naphthyl, indanyl, or tetrahydronaphthyl optionally substituted with alkyl alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, or amino.
- 10 12. The compound of claim 1, wherein A is phenyl, Y<sup>1</sup> is a bond, and L is a C<sub>6-12</sub> hydrocarbon chain containing three double bonds and the carbon adjacent to Y<sup>1</sup> is substituted with phenyl.
13. The compound of claim 1, wherein A is phenyl, Y<sup>1</sup> is a bond, and L is a C<sub>3-12</sub> hydrocarbon chain and the carbon adjacent to Y<sup>1</sup> is substituted with two phenyl  
15 groups.
14. The compound of claim 1, wherein the compound is 1,1,1-trifluoro-8-phenyl-3,5,7-octatrien-2-one or 1,1,1-trifluoro-8-phenoxy-3,5,7-octatrien-2-one.
15. A method of inhibiting histone deacetylation activity in cells comprising contacting the cells with an effective amount of a compound containing a trihalomethylcarbonyl group, thereby treating one or more disorders mediated by  
20 histone deacetylase or stimulating hematopoietic cells *ex vivo*, and  
determining whether the level of acetylated histones in the treated cells is higher than in untreated cells under the same conditions.
16. The method of claim 15; wherein the compound is of the formula (I):



wherein

A is a cyclic moiety selected from the group consisting of C<sub>3-14</sub> cycloalkyl, 3-14 membered heterocycloalkyl, C<sub>4-14</sub> cycloalkenyl, 3-8 membered heterocycloalkenyl, aryl, and heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, thio, alkylthio, arylthio, aralkylthio, acylthio, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl; or A is a saturated C<sub>1-12</sub> hydrocarbon chain or an unsaturated C<sub>2-12</sub> hydrocarbon chain optionally interrupted by -O-, -S-, -N(R<sup>a</sup>)-, -C(O)-, -N(R<sup>a</sup>)-SO<sub>2</sub>-, -SO<sub>2</sub>-N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-O-, -O-C(O)-N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-N(R<sup>b</sup>)-, -C(O)-N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-, -O-C(O)-, -C(O)-O-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, or -O-C(O)-O-, where each of R<sup>a</sup> and R<sup>b</sup>, independently, is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl; each of the saturated and the unsaturated branched hydrocarbon chain being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl;

each of Y<sup>1</sup> and Y<sup>2</sup>, independently, is -CH<sub>2</sub>-, -O-, -S-, -N(R<sup>c</sup>)-, -N(R<sup>c</sup>)-C(O)-O-, -C(O)-, -C(NOR<sup>c</sup>)-, -N(R<sup>c</sup>)-C(O)-, -C(O)-N(R<sup>c</sup>)-, -O-C(O)-N(R<sup>c</sup>)-, -N(R<sup>c</sup>)-C(O)-N(R<sup>d</sup>)-, -O-C(O)-O-, or a bond; each of R<sup>c</sup> and R<sup>d</sup>, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

L is a straight C<sub>1-12</sub> hydrocarbon chain optionally containing at least one double bond, at least one triple bond, or at least one double bond and one triple bond; the hydrocarbon chain being optionally substituted with C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, hydroxyl, halo, amino, nitro, cyano, C<sub>3-5</sub> cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C<sub>1-4</sub> alkylcarbonyloxy, C<sub>1-4</sub> alkyloxycarbonyl, C<sub>1-4</sub> alkylcarbonyl, or formyl; and further being optionally interrupted by -O-, -N(R<sup>e</sup>)-, -N(R<sup>e</sup>)-C(O)-O-, -O-C(O)-N(R<sup>e</sup>)-, -N(R<sup>e</sup>)-C(O)-N(R<sup>f</sup>)-, or -O-C(O)-O-; each of R<sup>e</sup> and R<sup>f</sup>, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

X<sup>1</sup> is O or S; and

X<sup>2</sup> is a halogen;



or a salt thereof.

17. The method of any of claims 15 or 16, wherein the disorder is selected from the group consisting of cancer, hemoglobinopathies, thalassemia, sickle cell anemia, cystic fibrosis, protozoan infection, spinal muscular atrophy, Huntington's disease, alpha-1 anti-trypsin, retrovirus gene vector reactivation, wound healing, hair growth, peroxisome biogenesis disorder, and adrenoleukodystrophy.

18. The method of any of claims 15 or 16, wherein the disorder is cancer, cystic fibrosis, or adrenoleukodystrophy.

19. The method of any of claims 15 or 16, wherein hematopoietic cells are stimulated *ex vivo*.

20. The method of claim 15, wherein the compound is 1,1,1-trifluoro-5-phenyl-2-pentanone, 1,1,1-trifluoro-8-phenyl-3,5,7-octatrien-2-one, or 1,1,1-trifluoro-8-phenoxy-3,5,7-octatrien-2-one.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US03/15996

| <p><b>A. CLASSIFICATION OF SUBJECT MATTER</b><br/>                 IPC(7) : C07C 69/63<br/>                 US CL : 560/227<br/>                 According to International Patent Classification (IPC) or to both national classification and IPC</p>   |  |   |  |   |   |  |  |  |  |  |  |   |  |         |
|--|--|---|--|---|---|--|--|--|--|--|--|---|--|---------|
| <p><b>B. FIELDS SEARCHED</b><br/>                 Minimum documentation searched (classification system followed by classification symbols)<br/>                 U.S. : 560/227<br/>                 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched<br/>                 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)<br/>                 STN CAPLUS, STRUCTURE SEARCH, ESAT, WEST</p>   |  |   |  |   |   |  |  |  |  |  |  |   |  |         |
| <p><b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b></p> <table border="1"> <thead> <tr> <th>Category *</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td>Database CAPLUS on STN, AN 1993:538742. NOZOE, S. 'Preparation of neocarzirin derivatives as anticancer agents'. JP 05070394 A2 (SHIGEO) 03 March 1993 (03.03.1993), Abstract.</td> <td>1, 5</td> </tr> <tr> <td>X</td> <td>Database CAPLUS on STN, AN 1986:130079. MEAD, D. et al. 'New Geometric Isomers of Vitamin A. 13 Fluorinated retinoids via crossed aldol condensation of 1,1,1-trifluoroacetone'. Tetrahedron Letters, 1985, Vol. 26, No. 24, pages 2873 to 2876, Abstract.</td> <td>1, 2, 5</td> </tr> <tr> <td>X</td> <td>Database CAPLUS on STN, AN 1998:732415. BRUMMOND K.M. et al. 'A New Method for the Preparation of Vinyl Triflates'. Tetrahedron Letters, 1998, Vol. 39, No. 47, pages 8613 - 8616, Abstract.</td> <td>1, 2, 5</td> </tr> </tbody> </table>   |  |   | Category *   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.   | X  | Database CAPLUS on STN, AN 1993:538742. NOZOE, S. 'Preparation of neocarzirin derivatives as anticancer agents'. JP 05070394 A2 (SHIGEO) 03 March 1993 (03.03.1993), Abstract. | 1, 5   | X  | Database CAPLUS on STN, AN 1986:130079. MEAD, D. et al. 'New Geometric Isomers of Vitamin A. 13 Fluorinated retinoids via crossed aldol condensation of 1,1,1-trifluoroacetone'. Tetrahedron Letters, 1985, Vol. 26, No. 24, pages 2873 to 2876, Abstract. | 1, 2, 5  | X | Database CAPLUS on STN, AN 1998:732415. BRUMMOND K.M. et al. 'A New Method for the Preparation of Vinyl Triflates'. Tetrahedron Letters, 1998, Vol. 39, No. 47, pages 8613 - 8616, Abstract. | 1, 2, 5 |
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.   |  |   |   |  |  |  |  |  |  |   |  |         |
| X  | Database CAPLUS on STN, AN 1993:538742. NOZOE, S. 'Preparation of neocarzirin derivatives as anticancer agents'. JP 05070394 A2 (SHIGEO) 03 March 1993 (03.03.1993), Abstract.   | 1, 5  |  |   |   |  |  |  |  |  |  |   |  |         |
| X  | Database CAPLUS on STN, AN 1986:130079. MEAD, D. et al. 'New Geometric Isomers of Vitamin A. 13 Fluorinated retinoids via crossed aldol condensation of 1,1,1-trifluoroacetone'. Tetrahedron Letters, 1985, Vol. 26, No. 24, pages 2873 to 2876, Abstract. | 1, 2, 5   |  |   |   |  |  |  |  |  |  |   |  |         |
| X  | Database CAPLUS on STN, AN 1998:732415. BRUMMOND K.M. et al. 'A New Method for the Preparation of Vinyl Triflates'. Tetrahedron Letters, 1998, Vol. 39, No. 47, pages 8613 - 8616, Abstract.   | 1, 2, 5   |  |   |   |  |  |  |  |  |  |   |  |         |
| <p><input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.</p>   |  |   |  |   |   |  |  |  |  |  |  |   |  |         |
| <p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"Z" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table> |  |   | "A" document defining the general state of the art which is not considered to be of particular relevance | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention | "E" earlier application or patent published on or after the international filing date | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone | "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)        | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art | "O" document referring to an oral disclosure, use, exhibition or other means | "Z" document member of the same patent family  | "P" document published prior to the international filing date but later than the priority date claimed |   |  |         |
| "A" document defining the general state of the art which is not considered to be of particular relevance   | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |   |  |   |   |  |  |  |  |  |  |   |  |         |
| "E" earlier application or patent published on or after the international filing date  | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |   |  |   |   |  |  |  |  |  |  |   |  |         |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art           |   |  |   |   |  |  |  |  |  |  |   |  |         |
| "O" document referring to an oral disclosure, use, exhibition or other means   | "Z" document member of the same patent family  |   |  |   |   |  |  |  |  |  |  |   |  |         |
| "P" document published prior to the international filing date but later than the priority date claimed   |  |   |  |   |   |  |  |  |  |  |  |   |  |         |
| <p>Date of the actual completion of the international search<br/>                 08 August 2003 (08.08.2003)</p>  |  | <p>Date of mailing of the international search report<br/>                 30 OCT 2003</p>                  |  |   |   |  |  |  |  |  |  |   |  |         |
| <p>Name and mailing address of the ISA/US<br/>                 Mail Stop PCT, Attn: ISA/US<br/>                 Commissioner for Patents<br/>                 P.O. Box 1450<br/>                 Alexandria, Virginia 22313-1450<br/>                 Facsimile No. (703)305-3230</p>  |  | <p>Authorized officer<br/>                 Allan Rotman<br/>                 Telephone No. 703-308-1235</p> |  |   |   |  |  |  |  |  |  |   |  |         |